NCT05027646View on ClinicalTrials.gov

Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches.

PHASE1CompletedINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

July 6, 2021

Primary Completion Date

December 22, 2021

Study Completion Date

January 19, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

Sancuso - Part 1

Part 1 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.

DRUG

Sancuso - Part 2

Part 2 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.

Trial Locations (1)

78744

PPD Development, Austin

Sponsors

Lead Sponsor

Kyowa Kirin, Inc.

Collaborators (1)

PPD Development, LP
All Listed Sponsors
collaborator

PPD Development, LP

INDUSTRY

lead

Kyowa Kirin, Inc.

INDUSTRY

NCT05027646 - Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches. | Biotech Hunter | Biotech Hunter